Purdue University Center for Paralysis Research
Borgens, Ph.D., decided to devote his life to the treatment of spinal
cord injuries after receiving a postdoctoral fellowship from the National
Paraplegia Foundation for study at Yale University. He attended the foundation's
annual convention and saw several hundred people in wheelchairs.
"A lot of them were in bad shape," says Borgens,
who earned his bachelor's degree in psychology and master's degree in
biology from UNT.
After completing the fellowship, Borgens returned to
Purdue University, where he had earned his doctoral degree. He founded
the university's Center for Paralysis Research in 1987.
center recently received FDA approval to implant devices producing weak
electrical fields about
1/250,000 of a volt
into humans with spinal cord injuries. Situated near the area of
an injury, the device, known as an extraspinal oscillating field stimulator
(OFS), will help to regenerate and guide growth in the damaged nerves.
It will stay in the body for 14 weeks, with the electrical flow periodically
reversed to guide nerve growth in both directions.
bodies produce natural electrical fields that control growth and development.
OFS units provide a way to generate growth when the natural fields are
disrupted through nerve injury," Borgens says. Borgens
and his researchers first tested OFS units on 13 dogs paralyzed by natural
causes. Seven of the dogs were walking within six months of receiving
the implants, and two walked as well as healthy dogs.
director, Texas Cancer Care
Cancer Care in Fort Worth, Ray Page, D.O., Ph.D., brings his love of research
and medicine to a clinical research practice that attracts some of the
nation's leading studies of new drug therapies.
therapies we have available to our TCC
patients are amazing," Page says. "This is the stuff you could usually
only get at a large academic medical center."
who earned his degrees in osteopathic medicine and pharmacology from the
UNT Health Science Center at Fort Worth in 1991, started the clinical
research program at Texas Cancer Care in 1998. The clinic now offers pharmaceutical
and government agencies one of the largest clinical oncology patient bases
available in one setting for studies of new drugs and treatments.
the novel drugs currently being tested at TCC is a one-time, one-dose
therapy for treating lymphoma. The drug is showing great success and should
be FDA-approved by the end of the year, Page says.
patients are benefiting from a career decision he made some time ago.
always intended to do research as my life work," he says. "I
went into oncology as a specialty because it was more amenable to trying
out new drugs —
so I could really use my pharmacology background.
was the right choice."
development director, Spectra Inc.
clear documents delivered from ink jet printers and digital displays on
cell phones, watches and laptops are possible thanks in part to the research
of Linda Truitt Creagh, Ph.D.
who earned her doctoral degree in chemistry, is a second-generation
UNT graduate. Her father, Price Truitt, received degrees from North Texas
and served as a distinguished faculty member in the chemistry department.
began her own research career at Texas Instruments in 1966.
was the first technical professional woman employed by TI," she says.
"The first project I worked on at its research laboratories dealt with
She also participated in the development of liquid
crystal displays used for calculators and watches.
her successful career with TI, Creagh accepted a position at Xerox, where
she led a project team in developing liquid crystal displays. After transferring
to the ink jet technology department, she worked on the development of
inks for printheads.
1984 Creagh co-founded Spectra Inc., a developer of ink jet printheads,
in Hanover, N.H. She has served the company as director of ink development
and director of engineering. She is currently business development director.
"No matter what my job title has been, my greatest accomplishment
is my role as a mentor of engineers," she says.